美国哈佛大学Benjamin L. Ebert、瑞士弗里德里希·米舍尔生物医学研究所Nicolas H. Thomä等研究人员合作发现,CDK抑制剂CR8可作为分子胶水来降解细胞周期素K。2020年6月3日,《自然》在线发表了这一成果。
Title: The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
Author: Mikoaj Sabicki, Zuzanna Kozicka, Georg Petzold, Yen-Der Li, Manisha Manojkumar, Richard D. Bunker, Katherine A. Donovan, Quinlan L. Sievers, Jonas Koeppel, Dakota Suchyta, Adam S. Sperling, Emma C. Fink, Jessica A. Gasser, Li R. Wang, Steven M. Corsello, Rob S. Sellar, Max Jan, Dennis Gillingham, Claudia Scholl, Stefan Frhling, Todd R. Golub, Eric S. Fischer, Nicolas H. Thom, Benjamin L. Ebert
Issue&Volume: 2020-06-03
Abstract: Molecular glue compounds induce protein–protein interactions that, in the context of a ubiquitin ligase, lead to protein degradation1. Unlike traditional enzyme inhibitors, these molecular glue degraders act substoichiometrically to catalyse the rapid depletion of previously inaccessible targets2. They are clinically effective and highly sought-after, but have thus far only been discovered serendipitously. Here, through systematically mining databases for correlations between the cytotoxicity of 4,518 clinical and preclinical small molecules and the expression levels of E3 ligase components across hundreds of human cancer cell lines3,4,5, we identify CR8—a cyclin-dependent kinase (CDK) inhibitor6—as a compound that acts as a molecular glue degrader. The CDK-bound form of CR8 has a solvent-exposed pyridyl moiety that induces the formation of a complex between CDK12–cyclin K and the CUL4 adaptor protein DDB1, bypassing the requirement for a substrate receptor and presenting cyclin K for ubiquitination and degradation. Our studies demonstrate that chemical alteration of surface-exposed moieties can confer gain-of-function glue properties to an inhibitor, and we propose this as a broader strategy through which target-binding molecules could be converted into molecular glues.
DOI: 10.1038/s41586-020-2374-x
Source: https://www.nature.com/articles/s41586-020-2374-x
Nature:《自然》,创刊于1869年。隶属于施普林格·自然出版集团,最新IF:69.504
官方网址:http://www.nature.com/
投稿链接:http://www.nature.com/authors/submit_manuscript.html
本期文章:《自然》:Online/在线发表